Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Applied Therapeutics stock

Own Applied Therapeutics stock in just a few minutes.

Applied Therapeutics, Inc is a biotechnology business based in the US. Applied Therapeutics shares (APLT) are listed on the NASDAQ and all prices are listed in US Dollars. Applied Therapeutics employs 24 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Applied Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – APLT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Applied Therapeutics share price

Use our graph to track the performance of APLT stocks over time.

Applied Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$13.58 - $51.99
50-day moving average $18.14
200-day moving average $20.57
Wall St. target price$49.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.69

Buy Applied Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Applied Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Applied Therapeutics financials

Gross profit TTM $0
Return on assets TTM -77.23%
Return on equity TTM -164.06%
Profit margin 0%
Book value $3.64
Market capitalisation $472.9 million

TTM: trailing 12 months

Shorting Applied Therapeutics shares

There are currently 1.5 million Applied Therapeutics shares held short by investors – that's known as Applied Therapeutics's "short interest". This figure is 4.9% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Applied Therapeutics shares can be evaluated.

Applied Therapeutics's "short interest ratio" (SIR)

Applied Therapeutics's "short interest ratio" (SIR) is the quantity of Applied Therapeutics shares currently shorted divided by the average quantity of Applied Therapeutics shares traded daily (recently around 99452.281616688). Applied Therapeutics's SIR currently stands at 15.34. In other words for every 100,000 Applied Therapeutics shares traded daily on the market, roughly 15340 shares are currently held short.

However Applied Therapeutics's short interest can also be evaluated against the total number of Applied Therapeutics shares, or, against the total number of tradable Applied Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Applied Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Applied Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0869% of the tradable shares (for every 100,000 tradable Applied Therapeutics shares, roughly 87 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Applied Therapeutics.

Find out more about how you can short Applied Therapeutics stock.

Applied Therapeutics share dividends

We're not expecting Applied Therapeutics to pay a dividend over the next 12 months.

Applied Therapeutics overview

Applied Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site